

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

UPDATE ON RESUMPTION

References are made to the announcements of China Wah Yan Healthcare Limited (the “Company”) dated 1 February, 11 March and 2 May 2019. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the above announcements.

RESUMPTION PLAN

The Company wishes to announce that following the engagement of a professional adviser to assist the Independent Committee in relation to the Investigation, the Independent Committee is taking active steps for the Investigation with a view to addressing the concern of the Commission and fulfilling the Resumption Conditions. The Company targets to complete the Investigation and announces its outstanding financial results as soon as practicable.

BUSINESS OPERATIONS

The Company has continued to carry on its principal businesses, including (i) health management business; (ii) medical and well-being business; and (iii) asset management business.

GENERAL

Trading in the shares of the Company will continue to be suspended since the Resumption Conditions have not been fulfilled. The Company will update its shareholders and potential investors on any material development relating to the resumption of trading in its shares as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the board of directors of
China Wah Yan Healthcare Limited
Chan Ka Chung
Chairman

Hong Kong, 2 August 2019

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Mr. Tsang Hung Kei.